Targeting the insulin-like growth factor network in cancer therapy

Cancer Biology and Therapy

Volumn 11, Issue 8, 2011, Pages 701-707

  Heidegger, Isabel ^a   Pircher, Andreas ^b   Klocker, Helmut ^a   Massoner, Petra ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b Hematology and Oncology ^*  (Austria)

Author keywords

Anti sense oligonucleotids; Cancer; IGF; IGF binding proteins; Monoclonal antibodies; Receptor targeting; Receptor tyrosine kinase inhibitors

Indexed keywords

AMG 479; AVE 1642; AXL 1717; BIIB 022; BMS 754807; CARBOPLATIN; CISPLATIN; DALOTUZUMAB; DOCETAXEL; DOXORUBICIN; ERLOTINIB; ETOPOSIDE; FIGITUMUMAB; GEFITINIB; GEMCITABINE; GOSERELIN; LIGAND; MONOCLONAL ANTIBODY; OSI 906; PACLITAXEL; PANITUMUMAB; PEMETREXED; PHOSPHATIDYLINOSITOL 3 KINASE; R 1507; SOMATOMEDIN; SOMATOMEDIN C RECEPTOR; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADVANCED CANCER; ANEMIA; APOPTOSIS; ASTHENIA; BINDING AFFINITY; BLEEDING; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER THERAPY; CARDIOPULMONARY INSUFFICIENCY; CELL DIFFERENTIATION; CELL PROLIFERATION; CEREBROVASCULAR DISEASE; CHILDHOOD CANCER; COLON CANCER; COLORECTAL CANCER; DEHYDRATION; DIGESTIVE SYSTEM CANCER; DRUG FATALITY; ENZYME ACTIVITY; FATIGUE; HEMOPTYSIS; HOMEOSTASIS; HUMAN; HYPERGLYCEMIA; IMMUNOHISTOCHEMISTRY; INFECTION; KIDNEY CANCER; LIGAND BINDING; LIVER CELL CARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; MULTIPLE CANCER; NEUROBLASTOMA; OVARY CANCER; OVERALL SURVIVAL; PANCREAS CANCER; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PROSTATE CANCER; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN INTERACTION; RETINOBLASTOMA; REVIEW; SARCOMA; SIGNAL TRANSDUCTION; SOFT TISSUE SARCOMA; SOLID TUMOR; THROMBOCYTOPENIA; THYMOMA;

ANTIBODIES, MONOCLONAL; CLINICAL TRIALS AS TOPIC; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; INSULIN-LIKE GROWTH FACTOR I; MOLECULAR TARGETED THERAPY; NEOPLASMS; OLIGORIBONUCLEOTIDES, ANTISENSE; PROTEIN BINDING; PROTEIN KINASE INHIBITORS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, IGF TYPE 1; SIGNAL TRANSDUCTION;

EID: 79954614279     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.11.8.14689     Document Type: Review

References (58)

1. Le Roith D. Seminars in medicine of the Beth Israel Deaconess Medical Center. Insulin-like growth factors. N Engl J Med 1997; 336:633-40.
2. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 2008; 8:915-28.
3. Riedemann J, Macaulay VM. IGF1R signalling and its inhibition. Endocr Relat Cancer 2006; 13:33-43.
4. Renehan AG, Frystyk J, Flyvbjerg A. Obesity and cancer risk: the role of the insulin-IGF axis. Trends Endocrinol Metab 2006; 17:328-36. (Pubitemid 44397568)
5. www.clinialtrials.gov. 1-6-2010.
6. Foulstone E, Prince S, Zaccheo O, Burns JL, Harper J, Jacobs C, et al. Insulin-like growth factor ligands, receptors and binding proteins in cancer. J Pathol 2005;205:145-53. (Pubitemid 40227987)
7. Pandini G, Frasca F, Mineo R, Sciacca L, Vigneri R, Belfiore A. Insulin/insulin-like growth factor I hybrid receptors have different biological characteristics depending on the insulin receptor isoform involved. J Biol Chem 2002; 277:39684-95. (Pubitemid 35190951)
8. Belfiore A, Frasca F, Pandini G, Sciacca L, Vigneri R. Insulin receptor isoforms and insulin receptor/insulinlike growth factor receptor hybrids in physiology and disease. Endocr Rev 2009; 30:586-623.
9. Gennigens C, Menetrier-Caux C, Droz JP. Insulin-Like Growth Factor (IGF) family and prostate cancer. Crit Rev Oncol Hematol 2006; 58:124-45.
10. Duan C, Ren H, Gao S. Insulin-like growth factors (IGFs), IGF receptors and IGF-binding proteins: roles in skeletal muscle growth and differentiation. Gen Comp Endocrinol 2010; 167:344-51.
11. Pollak M. Insulin-like growth factor-related signaling and cancer development. Recent Results Cancer Res 2007; 174:49-53.
12. Palazzo A, Iacovelli R, Cortesi E. Past, present and future of targeted therapy in solid tumors. Curr Cancer Drug Targets 2010; 10:433-61.
13. Chen B, Liu S, Xu W, Wang X, Zhao W, Wu J. IGF-I and IGFBP-3 and the risk of lung cancer: a metaanalysis based on nested case-control studies. J Exp Clin Cancer Res 2009; 28:89.
14. Wheeler DL, Dunn EF, Harari PM. Understanding resistance to EGFR inhibitors-impact on future treatment strategies. Nat Rev Clin Oncol 2010; 7:493-507.
15. Arteaga CL, Osborne CK. Growth inhibition of human breast cancer cells in vitro with an antibody against the typeI somatomedin receptor. Cancer Res 1989; 49:6237-41. (Pubitemid 20000915)
16. Zha J, Lackner MR. Targeting the insulin-like growth factor receptor-1R pathway for cancer therapy. Clin Cancer Res 2010; 16:2512-7.
17. Kull FC Jr, Jacobs S, Su YF, Svoboda ME, Van Wyk JJ, Cuatrecasas P. Monoclonal antibodies to receptors for insulin and somatomedin-C. J Biol Chem 1983;258:6561-6. (Pubitemid 13106829)
18. Pfizer. Press release from Pfizer: Pfizer discontinues a phase III trail of figitumumab in non-small cell lung cancer (NSCLC). Press release 12/29/2009 and 3/11/2010.
19. Jassem J, Langer CJ, Karp DD, Mok T, Benner RJ, Green SJ, et al. Randomized, open label, phase III trial of figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin in patients with non-small cell lung cancer (NSCLC). J Clin Oncol 2010; 28:15.
20. Ohlsson C, Mohan S, Sjogren K, Tivesten A, Isgaard J, Isaksson O, et al. The role of liver-derived insulin-like growth factor-I. Endocr Rev 2009;30:494-535.
21. Gualberto A. Figitumumab (CP-751,871) for cancer therapy. Expert Opin Biol Ther 2010; 10:575-85.
22. Hart LS, Dicker DT, Grimberg A, Christensen J, El-Deiry W. The fully human IGF-1 receptor antibody, CP-751,871, targets putative colon cancer stem cell populations. AACR Annual Meeting 2010.
23. Pircher A, Ploner F, Popper H, Hilbe W. Rationale of a relaunch of gefitinib in Caucasian non-small cell lung cancer patients. Lung Cancer 2010; 69:265-71.
24. Norum J, Nieder C, Kondo M. Sunitinib, sorafenib, temsirolimus or bevacizumab in the treatment of metastatic renal cell carcinoma: a review of health economic evaluations. J Chemother 2010; 22:75-82.
25. Weinberg R, Ed.. The Biology of Cancer. London, England: Garland Science, 2008.
26. Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Shringarpure R, Akiyama M, et al. Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies and solid tumors. Cancer Cell 2004; 5:221-30. (Pubitemid 38402114)
27. Scotlandi K, Manara MC, Nicoletti G, Lollini PL, Lukas S, Benini S, et al. Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors. Cancer Res 2005; 65:3868-76. (Pubitemid 40616368)
28. Wolf S, Lorenz J, Mossner J, Wiedmann M. Treatment of biliary tract cancer with NVP-AEW541: mechanisms of action and resistance. World J Gastroenterol 2010; 16:156-66.
29. Desai J, Solomon BJ, Davis ID, Lipton LR, Hicks R, Scott AM, et al. Phase I dose-escalation study of daily BMS-754807, an oral, dual IGF-1R/insulin receptor (IR) inhibitor in subjects with solid tumors. J Clin Oncol 2010; 28:15.
30. Evans T, Lindsay CR, Chan E, Tait B, Michael SA, Day S, et al. Phase I dose-escalation study of continuous oral dosing of OSI-906, a dual tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR), in patients with advanced solid tumors. J Clin Oncol 2010; 28:15.
31. Carden CP, Kim ES, Jones RL, Alam SM, Johnson FM, Stephens AW, et al. Phase I study of intermittent dosing of OSI-906, a dual tyrosine kinase inhibitor of insulinlike growth factor-1 receptor (IGF-1R) and insulin receptor (IR) in patients with advanced solid tumors. J Clin Oncol 2010; 28:15.
32. Rajpathak SN, Gunter MJ, Wylie-Rosett J, Ho GY, Kaplan RC, Muzumdar R, et al. The role of insulinlike growth factor-I and its binding proteins in glucose homeostasis and type 2 diabetes. Diabetes Metab Res Rev 2009; 25:3-12.
33. Yee D. Targeting insulin-like growth factor pathways. Br J Cancer 2006; 94:465-8. (Pubitemid 43289747)
34. Yin M, Guan X, Liao Z, Wei Q. Insulin-like growth factor-1 receptor-targeted therapy for non-small cell lung cancer: a mini review. Am J Transl Res 2009; 1:101-14.
35. Belfiore A. The role of insulin receptor isoforms and hybrid insulin/IGF-I receptors in human cancer. Curr Pharm Des 2007; 13:671-86. (Pubitemid 46510744)
36. Di Cresce C, Koropatnick J. Antisense treatment in human prostate cancer and Melanoma. Curr Cancer Drug Targets 2010; 1:555-65.
37. Sachdev D, Yee D. Disrupting insulin-like growth factor signaling as a potential cancer therapy. Mol Cancer Ther 2007; 6:1-12. (Pubitemid 46206663)
38. Shen YM, Yang XC, Yang C, Shen JK. Enhanced therapeutic effects for human pancreatic cancer by application K-ras and IGF-IR antisense oligodeoxynucleotides. World J Gastroenterol 2008; 14:5176-85.
39. Liu S, Jin F, Dai W, Yu Y. Antisense treatment of IGF-IR enhances chemosensitivity in squamous cell carcinomas of the head and neck. Eur J Cancer 2010; 46:1744-51.
40. Furukawa J, Wraight CJ, Freier SM, Peralta E, Atley LM, Monia BP. Antisense oligonucleotide targeting of insulin-like growth factor-1 receptor (IGF-1R) in prostate cancer. Prostate 2010; 70:206-18.
41. Furukawa J, Wraight CJ, Monia BP, Gleave ME, Cox ME. Antisense oligonucleotide targeting insulin-like growth factor-1 receptor (IGF-1R) enhances paclitaxel sensitivity in a castrate-resistant and paclitaxel-resistant prostate cancer model. AACR Annual Meeting 2010.
42. Andrews DW, Resnicoff M, Flanders AE, Kenyon L, Curtis M, Merli G, et al. Results of a pilot study involving the use of an antisense oligodeoxynucleotide directed against the insulin-like growth factor type I receptor in malignant astrocytomas. J Clin Oncol 2001; 19:2189-200. (Pubitemid 32366973)
43. Weroha SJ, Haluska P. IGF-1 receptor inhibitors in clinical trials-early lessons. J Mammary Gland Biol Neoplasia 2008; 13:471-83.
44. Samani AA, Yakar S, LeRoith D, Brodt P. The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev 2007; 28:20-47. (Pubitemid 46220849)
45. Grimberg A, Cohen P. Role of insulin-like growth factors and their binding proteins in growth control and carcinogenesis. J Cell Physiol 2000; 183:1-9. (Pubitemid 30130219)
46. Grimberg A. p53 and IGFBP-3: apoptosis and cancer protection. Mol Genet Metab 2000; 70:85-98. (Pubitemid 30460451)
47. Yamada PM, Lee KW. Perspectives in mammalian IGFBP-3 biology: local vs. systemic action. Am J Physiol Cell Physiol 2009; 296:954-76.
48. Massoner P, Colleselli D, Matscheski A, Pircher H, Geley S, Jansen DP, et al. Novel mechanism of IGFbinding protein-3 action on prostate cancer cells: inhibition of proliferation, adhesion and motility. Endocr Relat Cancer 2009; 16:795-808.
49. Liu B, Lee KW, Anzo M, Zhang B, Zi X, Tao Y, et al. Insulin-like growth factor-binding protein-3 inhibition of prostate cancer growth involves suppression of angiogenesis. Oncogene 2007; 26:1811-9. (Pubitemid 46426204)
50. Alami N, Page V, Yu Q, Jerome L, Paterson J, Shiry L, et al. Recombinant human insulin-like growth factorbinding protein 3 inhibits tumor growth and targets the Akt pathway in lung and colon cancer models. Growth Horm IGF Res 2008; 18:487-96.
51. Belizon A, Balik E, Kirman I, Remotti H, Ciau N, Jain S, et al. Insulin-like growth factor binding protein-3 inhibits colitis-induced carcinogenesis. Dis Colon Rectum 2007; 50:1377-83. (Pubitemid 47472388)
52. Schumacher FR, Cheng I, Freedman ML, Mucci L, Allen NE, Pollak MN, et al. A comprehensive analysis of common IGF1, IGFBP1 and IGFBP3 genetic variation with prospective IGF-I and IGFBP-3 blood levels and prostate cancer risk among Caucasians. Hum Mol Genet 2010; 19:3089-101.
53. Sachdev D, Sarver A. The type I insulin-like growth factor receptor (IGF1R) pathway driven metastasis signature correlates with poor prognosis and decreased distant metastasis-free survival in human breast cancer. AACR Annual Meeting 2010.
54. de Bono JS, Attard G, Adjei A, Pollak MN, Fong PC, Haluska P, et al. Potential applications for circulating tumor cells expressing the insulin-like growth factor-I receptor. Clin Cancer Res 2007; 13:3611-6. (Pubitemid 46955123)
55. Huang F, Greer A, Hurlburt W, Han X, Hafezi R, Wittenberg GM, et al. The mechanisms of differential sensitivity to an insulin-like growth factor-1 receptor inhibitor (BMS-536924) and rationale for combining with EGFR/HER2 inhibitors. Cancer Res 2009; 69:161-70.
56. Chung CH, Pohlmann PR, Rothenberg ML, Burkey BB, Parker J, Palka K, et al. Insulin-like growth factor-1 receptor inhibitor, AMG-479, in cetuximab-refractory head and neck squamous cell carcinoma. Head Neck 2010; (In print).
57. Bareschino MA, Morgillo F, Ciardiello F. Combination of standard chemotherapy and targeted agents. J Thorac Oncol 2007; 2:19-23.
58. Takhar S, Periyasamy-Thandavan S, Jackson WH, Singer A, Herberg S, Hill W, et al. IGF1 attenuates autophagic catabolism and apoptotic cell death in hormonally treated breast cancer cells via a MEK1 pathway. AACR Annual Meeting 2010.